TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at two Israeli conferences in May, 2014.
|Oppenheimer 15th Annual Israeli Investor Conference|
|Date:||Sunday, May 11, 2014|
|Time:||7:10am Eastern/1:10pm GMT +2|
|Location:||David Intercontinental Hotel in Tel-Aviv|
|MIXiii/BioMed Israel Innovation Conference|
|Date:||Wednesday, May 21, 2014|
|Panel Title:||"Riding the IPO Wave"|
|Time:||9am Eastern/3pm GMT +2|
|Company Presentation||11am Eastern/5pm GMT +2|
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder, and is enrolling patients in a Phase III study for this indication in adults. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts: LifeSci Advisors, LLC Michael Rice 646-597-6979 email@example.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 firstname.lastname@example.org
|Alcobra Ltd. to Present at the Gordon Research Conference on Fragile X and Autism-Related Disorders|
|Alcobra Ltd. to Release First Quarter 2014 Results and Host Investor Conference Call on Thursday, May 15, 2014|
|Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly Inattentive ADHD at APA Annual Meeting|
|Galectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company's Annual Meeting of Shareholders|
|Regal Beloit Corporation To Present At The Oppenheimer 9th Annual Industrials Conference|
|Mandalay Resources Corporation provides notice of first quarter 2014 financial results and conference call (2014/4/30)|